# OnCo record nct04129502 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04129502/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04129502", "NCT04129502" ;
  schema:name "TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations"@en ;
  schema:description "A phase 3 trial of Mobocertinib, Pemetrexed, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Takeda, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04129502/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04129502> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-01-10" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/mobocertinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04129502-j-clin-oncol-2025/> .